Hescoe obtains Drug Registration Certificate for Grelo tablets

On January 31, Hesco announced that Its wholly-owned subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., had recently received the "Drug Registration Certificate" issued by the State Drug Administration.
Atrophics: Used in combination with aspirin for patients with acute coronary syndrome (ACS) or with a history of myocardial infarction and with at least one high risk factor for atherosclerosis thrombosis events (see clinical trial PEGASUS study), reducing the incidence of cardiovascular death, myocardial infarction, and stroke.
September 2018, Sichuan Haisco Pharmaceutical Co., Ltd. submitted an application for the production of Grelo tablets to the State Drug Administration and was accepted.
January 2021, Hesco Pharmaceuticals (Meishan) Co., Ltd. was officially approved for production and obtained the Drug Registration Certificate.
is a new type of oral antiplatelet drug CPTP, which is reversible to block platelet P2Y12 subjects.
is the first oral antiplate plateped drug to be shown to significantly reduce cardiovascular death and total fatality in patients with acute coronary artery syndrome, while significantly reducing the risk of cardiovascular events without increasing bleeding.
inquiry, the original development agent of the Tigrillo tablet was developed by AstraZeneca of Sweden and was approved by the European Union (EMA) for listing in Europe in December 2010 with the product name BRILIQUE®, with a specification of 90mg, 2016 In February 2011, the EMA approved the listing of 60mg specifications, the original development agent of the Tigrillo tablet was approved by the FDA in July 2011 for listing in the United States under the name BRILINTA®, with a specification of 90mg, and the 60mg specification was approved for listing in September 2015.
March 2013, Tigrillo tablets were approved for import (H20120486), with a specification of 90 mg and a product named ®.
approved for import on June 60, 2017 (H20171037).
our company's product in accordance with the quality of generic drugs and efficacy of the evaluation of registration declaration, approval is the same as the adoption of consistency evaluation.
the product is currently listed in addition to 3 original research manufacturers (AstraZeneca AB), but also Shenzhen Xinlitai Pharmaceutical Co., Ltd. and other eight pharmaceutical companies listed.
2019 sales of more than 1.5 billion yuan in urban public and county-level public hospitals, and nearly 900 million yuan in the first half of 2020, according to Mienet data.